| 词条 | Meglitinide |
| 释义 |
They bind to an ATP-dependent K+ (KATP) channel on the cell membrane of pancreatic beta cells in a similar manner to sulfonylureas but have a weaker binding affinity and faster dissociation from the SUR1 binding site. This increases the concentration of intracellular potassium, which causes the electric potential over the membrane to become more positive. This depolarization opens voltage-gated Ca2+ channels. The rise in intracellular calcium leads to increased fusion of insulin granulae in the cell membrane, and therefore increased secretion of (pro) insulin. DrugsThe main branded drug in the meglitinide class is Novo Nordisk's repaglinide (Prandin), which gained FDA approval in 1997. Other drugs in this class include nateglinide (Starlix) and mitiglinide (Glufast). Side-effectsSide effects include weight gain and hypoglycemia. While the potential for hypoglycemia is less than for those on sulfonylureas, it is still a serious potential side effect that can be life-threatening. Patients on this medication should know the signs and symptoms of hypoglycemia and appropriate management. Repaglinide (Prandin) caused an increased incidence in male rats of benign adenomas (tumors) of the thyroid and liver.[2] No such effect was seen with another drug of this class, nateglinide (Starlix).[3] References1. ^{{cite journal |author=Blicklé JF |title=Meglitinide analogues: a review of clinical data focused on recent trials |journal=Diabetes Metab. |volume=32 |issue=2 |pages=113–20 |date=April 2006 |pmid=16735959 |doi= 10.1016/S1262-3636(07)70257-4|url=http://www.masson.fr/masson/MDOI-DM-04-2006-32-2-1262-3636-101019-200517724}} {{pharma-stub}}{{Oral_hypoglycemics}}2. ^Prandin (repaglinide) prescribing information, fda.gov 3. ^Starlix (nateglinide) prescribing information, fda.gov 1 : Meglitinides |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。